About AOP Orphan
Since its establishment 1996, AOP Orphan has focused on finding innovative solutions for Rare Diseases. Today AOP Orphan is a European pioneer in the field of Rare Diseases.

AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com


Hauptinhalt

A Pioneer in Rare Diseases

AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. Today AOP Orphan is active at an international level with an export ratio of about 70% and has become a leading company in its home market.

News

AOP Orphan Pharmaceuticals AG announced today that it has acquired Selisistat, a highly selective SIRT1 inhibitor, which in experimental studies has previously shown...

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics,...